Intravenous Micronutrient Therapy (IVMT) for Fibromyalgia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00067405 |
Recruitment Status :
Completed
First Posted : August 20, 2003
Last Update Posted : April 22, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Fibromyalgia | Drug: Intravenous micronutrient therapy | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Intravenous Micronutrient Therapy (IVMT) for Fibromyalgia |
Study Start Date : | June 2004 |
Actual Primary Completion Date : | July 2007 |
Actual Study Completion Date : | July 2007 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
- Meet the American College of Rheumatology criteria for Fibromyalgia diagnosis;
-
On no medication for Fibromyalgia other than acetaminophen, or willing to stop all such medication for the duration of the study
- Willing to stop all FMS medication for the duration of the study or be on a stable dose of such medication for at least 3 months
Exclusion criteria:
-
Other concurrent medical conditions such as rheumatologic disease, chronic infection, untreated endocrine disorders, unstable seizures, psychiatric disorders, acute peptic ulcer disease, congestive heart failure, chronic liver disorders and/or bleeding problems
- Allergy to thiamin
-
Unwilling to stop vitamin supplementation for the duration of the study
- PLEASE NOTE: Travel to and accomodations at the study site can NOT be compensated. Anyone wishing to travel from outside of the study site's geographic area must do so at their own risk and expense.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00067405
United States, Connecticut | |
Yale-Griffin Prevention Research Center | |
Derby, Connecticut, United States, 06418 |
Principal Investigator: | David Katz, MD | Yale-Griffin Prevention Research Center |
ClinicalTrials.gov Identifier: | NCT00067405 |
Other Study ID Numbers: |
R21AT000942-01A1 ( U.S. NIH Grant/Contract ) Katz |
First Posted: | August 20, 2003 Key Record Dates |
Last Update Posted: | April 22, 2008 |
Last Verified: | April 2008 |
Fibromyalgia Intravenous micronutrient therapy IVMT alternative medicine |
complementary medicine vitamins vitamin supplements |
Fibromyalgia Myofascial Pain Syndromes Muscular Diseases Musculoskeletal Diseases Rheumatic Diseases |
Neuromuscular Diseases Nervous System Diseases Micronutrients Trace Elements Physiological Effects of Drugs |